Board Meeting4 Nov 2026, 01:50 pm
Dr. Lal PathLabs Approves Q2 Results, ₹5 Dividend, Director Appointment
AI Summary
Dr. Lal PathLabs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also declared a second interim dividend of INR 5 per equity share for FY 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director (Non-Executive Independent Director) for a three-year term, subject to shareholder approval. The company also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business operations and investments in its own subsidiary, Sunshine Healthcare Limited (SHL), Ghana.
Key Highlights
- Approved unaudited financial results for Q2 and H1 FY2026-27.
- Declared 2nd interim dividend of ₹5 per share for FY2026-27.
- Appointed Ms. Vasuta Agarwal as Additional Non-Executive Independent Director.
- Approved further investment up to ₹49.5 Crores in subsidiary LPL Dubai.
Price Impact
More from LALPATHLAB